Repligen (RGEN) Stock Overview
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
RGEN Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Repligen Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$165.18 |
| 52 Week High | US$188.73 |
| 52 Week Low | US$100.99 |
| Beta | 1.05 |
| 1 Month Change | -0.31% |
| 3 Month Change | 26.49% |
| 1 Year Change | 45.48% |
| 3 Year Change | -0.19% |
| 5 Year Change | -46.18% |
| Change since IPO | 1,511.51% |
Recent News & Updates
Narrative Update • Sep 04
RGEN: Cancer Vaccine Exposure And Bioprocess Deals Will Shape Outlook
Analysts have nudged their price expectations for Repligen modestly higher, with the fair value estimate moving from about $182.05 to $187.70. This shift reflects updated views on its exposure to Moderna's cancer vaccine program, recent price target increases from several firms, and revised assumptions for revenue growth and profitability.
Narrative Update • Aug 20
RGEN: Cancer Vaccine Hype And BioLife Deal Will Test Overstretched Expectations
Analysts have raised the implied fair value for Repligen to about $145.92 from $142, reflecting updated assumptions for revenue growth, profit margins, discount rate and future P/E that are supported by recent research highlighting exposure to Moderna's cancer vaccine work, a series of higher external price targets, and a constructive view on bioprocessing demand. Analyst Commentary Recent Street research around Repligen gives you a mix of enthusiasm around new modalities and bioprocessing demand, along with some caution on valuation, sector sentiment, and execution risks.Narrative Update • Jul 29
RGEN: Cell Therapy Deal And Gene Therapy Lap Will Drive Upside
Analysts have nudged their fair value estimate for Repligen higher to about $182 from roughly $176, citing stronger expectations for revenue growth and sector valuations, supported by recent price target increases and rating upgrades across the Street. Analyst Commentary Recent Street research on Repligen gives you a mix of optimism about long term growth drivers and caution about sector sentiment, which helps explain the modest lift in fair value estimates.Recent updates
Narrative Update • Sep 04
RGEN: Cancer Vaccine Exposure And Bioprocess Deals Will Shape Outlook
Analysts have nudged their price expectations for Repligen modestly higher, with the fair value estimate moving from about $182.05 to $187.70. This shift reflects updated views on its exposure to Moderna's cancer vaccine program, recent price target increases from several firms, and revised assumptions for revenue growth and profitability.Narrative Update • Aug 20
RGEN: Cancer Vaccine Hype And BioLife Deal Will Test Overstretched Expectations
Analysts have raised the implied fair value for Repligen to about $145.92 from $142, reflecting updated assumptions for revenue growth, profit margins, discount rate and future P/E that are supported by recent research highlighting exposure to Moderna's cancer vaccine work, a series of higher external price targets, and a constructive view on bioprocessing demand. Analyst Commentary Recent Street research around Repligen gives you a mix of enthusiasm around new modalities and bioprocessing demand, along with some caution on valuation, sector sentiment, and execution risks.Narrative Update • Jul 29
RGEN: Cell Therapy Deal And Gene Therapy Lap Will Drive Upside
Analysts have nudged their fair value estimate for Repligen higher to about $182 from roughly $176, citing stronger expectations for revenue growth and sector valuations, supported by recent price target increases and rating upgrades across the Street. Analyst Commentary Recent Street research on Repligen gives you a mix of optimism about long term growth drivers and caution about sector sentiment, which helps explain the modest lift in fair value estimates.Narrative Update • Jun 27
RGEN: Bioprocess Recovery And Clean Gene Therapy Lap Will Drive Future Upside
Analysts reduced the fair value estimate for Repligen to $176.11 from $183.88 and lowered the implied future P/E assumption to about 80x from roughly 100x, citing sector wide price target cuts, even as some research points to early signs of recovery in bioprocessing and confidence in the company's balance sheet and product positioning. Analyst Commentary Street research on Repligen highlights a mix of optimism about the bioprocessing recovery and caution around valuation and sector sentiment.Narrative Update • Jun 13
RGEN: Bioprocess Recovery And Training Hub Expansion Will Guide Future Performance
Repligen's analyst price target has been reset slightly lower to $142, as analysts factor in a modestly higher discount rate along with still-supportive views on bioprocessing demand and the broader life science tools recovery. Analyst Commentary Recent Street research around Repligen reflects a mixed setup, with several firms trimming price targets and a few others highlighting potential recovery in bioprocessing demand.Seeking Alpha • May 31
Repligen Has A Cleaner Recovery Angle, But With High Valuation
Summary Repligen is recovering after a difficult 2024, with Q1 2026 revenue up 15% and 11% organic. Polymem, China, PAT, and the Transformation Office make the story cleaner, but execution still matters. I like Repligen's balance sheet, as it has plenty of liquidity with good cash flows to continue funding M&A deals or potential growth in Asia. Unfortunately, my main issue with RGEN is its expensive valuation, which leaves little margin of safety for investors at these levels. Read the full article on Seeking AlphaNarrative Update • May 30
RGEN: Firmer Bioprocess Backdrop And Hubs Expansion Will Shape Long Term Outlook
Repligen's updated analyst price target of $142 reflects a largely unchanged fair value. Analysts point to a mix of reduced P/E assumptions and slightly stronger expectations for revenue growth and profitability, supported by recent research that highlights a firmer bioprocess backdrop and diversified growth drivers.Narrative Update • May 11
RGEN: Recalibrated Street Expectations And Hubs Expansion Will Shape Long Term Outlook
Analysts now place Repligen's fair value at $142, a $2 adjustment that reflects a mix of recent price target cuts and increases as they weigh updated growth expectations, margins, and P/E assumptions from the latest round of Street research. Analyst Commentary The latest Street research on Repligen shows a split tape, with some firms lifting targets and others cutting them, which nets out to the modest US$2 bump in the aggregated fair value estimate to US$142.Narrative Update • Apr 25
RGEN: recalibrated Street Expectations Will Shape Bullish Long Term Outlook
The analyst price target for Repligen has been reduced from about $160.90 to $140.00, as analysts factor in updated assumptions for revenue growth, profit margins, discount rates and future P/E following a mix of recent target cuts and one upward revision across the Street. Analyst Commentary Street research on Repligen over recent months points to a mixed but generally more cautious stance, with several firms trimming price targets while one research house lifted its target.Narrative Update • Apr 09
RGEN: Multi Year Guidance And M&A Dry Powder Will Support Future Upside
Narrative Update on Repligen The analyst price target for Repligen has been adjusted slightly lower, with the updated fair value moving from about $186.82 to $183.88 as analysts factor in recent target cuts, alongside generally positive views on guidance and execution. Analyst Commentary Recent Street research on Repligen clusters around a group of target cuts following the latest Q4 report and FY26 outlook, alongside a smaller number of target increases.Narrative Update • Mar 25
RGEN: Multi Year Guidance And M&A Focus Will Support Future Upside
Repligen's analyst price target has been adjusted modestly higher to $186.82, with analysts pointing to refreshed assumptions around revenue growth, profit margins, and future P/E expectations following recent target changes across firms such as H.C. Wainwright, UBS, Evercore ISI, Wells Fargo, and Barclays. Analyst Commentary Recent target changes reflect a mix of optimism and caution around Repligen, with analysts adjusting their models after the latest Q4 results and FY26 guidance.Narrative Update • Mar 10
RGEN: M&A And New Bioprocessing Resins Will Support Future Upside
Narrative Update: Repligen Repligen's updated analyst price target reflects a modest reset, with fair value moving from about $190.89 to $186.28 as analysts factor in slightly lower revenue growth and profit margin assumptions along with a marginally higher discount rate, while still generally highlighting solid recent execution and cautious company guidance. Analyst Commentary Recent Street research on Repligen shows a mixed but generally constructive stance, with several firms trimming price targets while maintaining positive ratings.Narrative Update • Feb 24
RGEN: M&A Focus And New Bioprocessing Resins Will Drive Future Upside
Analysts have raised their Repligen price target by $10 to $190.89, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E as reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$190.89 price target as better aligned with updated assumptions for discount rates and future P/E, suggesting the shares may not fully reflect their revised valuation framework.Narrative Update • Feb 09
RGEN: M&A Ambitions And New Resins Portfolio Will Shape Bullish Outlook
Analysts have lifted their price target on Repligen by US$10, citing updated assumptions that reflect revised fair value estimates, a tweaked discount rate, adjusted revenue growth and profit margin expectations, and an updated future P/E multiple. Analyst Commentary Even with the higher price target, some research commentary points to risks that readers should keep in mind when weighing Repligen at current levels.Narrative Update • Jan 26
RGEN: Process Analytics Strength And Biopharma Recovery Will Support Further Upside
Analysts have nudged their price targets on Repligen higher, with our updated fair value estimate moving modestly to about US$190.89 per share. This is supported by recent Street research citing raised targets following a 3Q25 revenue beat and a relatively improving biopharma outlook, with growth across all franchises led by Process Analytics.Narrative Update • Jan 12
RGEN: Process Analytics Strength And Biopharma Recovery Will Support Upside In 2025
Analysts have lifted their price target on Repligen to about US$190 from US$187, pointing to recent target raises, including Canaccord's move to US$165 on 3Q25 revenue outperformance, a relatively improving biopharma outlook, and solid contributions from Process Analytics and other franchises. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a higher price target as a reflection of stronger than expected 3Q25 revenue, which they view as supportive of the current valuation range.Narrative Update • Dec 27
RGEN: Process Analytics Momentum And Biopharma Recovery Will Shape Risk Balanced Outlook
Narrative Update We are raising our Repligen fair value estimate from $131.29 to $160.36 per share as analysts lift price targets toward $160 to $165 on better than expected Q3 results, broad-based revenue growth led by Process Analytics, and an improving outlook for biopharma end markets. Analyst Commentary Recent Street research reflects a cautiously constructive stance on Repligen, with higher price targets acknowledging near term execution outperformance while still embedding meaningful risk around sustainability of growth.
Narrative Update • Dec 13
RGEN: Bioprocessing Recovery And Guidance Raise Will Support Upside Potential
Analysts have nudged our Repligen price target higher to $165, reflecting a modest trim to fair value estimates to about $216.62 per share, alongside slightly lower long term revenue growth and discount rate assumptions, but reinforced by recent target increases from the Street on better than expected quarterly results, improving biopharma demand, and confidence in the company s bioprocessing driven double digit growth potential. Analyst Commentary Bullish analysts have become incrementally more constructive on Repligen following its recent quarterly performance, citing a healthier biopharma demand backdrop and stronger than expected execution across key franchises.Narrative Update • Nov 27
RGEN: Volume Recovery and End-Market Stability Will Support Measured Upside in 2025
Narrative Update on Repligen Analysts have raised their price targets on Repligen by up to $15. They cite stronger-than-expected quarterly results and improved industry outlooks as driving positive momentum for the company.Analysis Article • Nov 12
Repligen's (NASDAQ:RGEN) Earnings May Just Be The Starting Point
Even though Repligen Corporation ( NASDAQ:RGEN ) posted strong earnings, investors appeared to be underwhelmed. We did...Narrative Update • Nov 11
RGEN: End-Market Improvements Will Drive Stronger Momentum Through 2025
Analysts have increased their price target for Repligen slightly, from $184.76 to $187.00. They cite a recent revenue beat, an improving sector outlook, and expectations for continued growth across key business areas.Analysis Article • Oct 31
Repligen Corporation Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next
Repligen Corporation ( NASDAQ:RGEN ) investors will be delighted, with the company turning in some strong numbers with...Narrative Update • Oct 28
Recovery In Industry Demand And Market Stability Will Drive Renewed Momentum
Repligen's analyst price target has been increased from $179.78 to $184.76, as analysts see improving market stability and anticipate a return to stronger revenue growth despite recent headwinds. Analyst Commentary Recent updates from street research highlight a renewed sense of optimism among analysts, along with acknowledgment of ongoing industry challenges.Analysis Article • Oct 04
Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge
Repligen Corporation ( NASDAQ:RGEN ) shares have had a really impressive month, gaining 28% after a shaky period...New Narrative • May 26
Biomanufacturing Expansion Will Create New Global Opportunities
Strong demand in biomanufacturing and effective market expansion are driving sustained revenue growth and improved margins for Repligen.Seeking Alpha • Mar 20
Repligen: Ongoing Bioprocessing Market Recovery
Summary I reiterate a 'buy' rating for Repligen with a one-year price target of $175 per share, driven by strong bioprocessing market recovery. Repligen reported 3% organic revenue growth and 13% growth in non-COVID business, with record-high order intakes since Q2 FY22. The acquisition of 908 Devices' bioprocessing analytics portfolio enhances Repligen's process analytical technology, adding significant value to its offerings. Despite challenges in the protein business, I expect 12% organic revenue growth in FY25, supported by new product launches and market normalization. Read the full article on Seeking AlphaSeeking Alpha • Nov 12
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects
Summary Repligen Corporation is a bioprocessing technology company focusing on process intensification, purification, and fluid management, with strategic acquisitions to enhance its capabilities. Though integration risks remain, RGEN's recent acquisition of Tantti Laboratory aims to bolster its chromatography and biomolecule purification capacities. The potential acquisition of Maravai LifeSciences could impact RGEN's future growth, but past failed attempts and divestment plans add uncertainty. Also, I believe international revenue exposure and foreign exchange volatility present additional risks for RGEN’s near-term financial performance. Despite a healthy underlying business, RGEN faces valuation concerns, tax loss harvesting, and uncertain growth, leading to a "Hold" rating ahead of its earnings report. Read the full article on Seeking AlphaShareholder Returns
| RGEN | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -1.4% | -3.8% | -2.2% |
| 1Y | 45.5% | 20.7% | 13.1% |
Return vs Industry: RGEN exceeded the US Life Sciences industry which returned 20.7% over the past year.
Return vs Market: RGEN exceeded the US Market which returned 13.1% over the past year.
Price Volatility
| RGEN volatility | |
|---|---|
| RGEN Average Weekly Movement | 7.0% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: RGEN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RGEN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 2,000 | Olivier Loeillot | www.repligen.com |
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Repligen Corporation Fundamentals Summary
| RGEN fundamental statistics | |
|---|---|
| Market cap | US$9.29b |
| Earnings (TTM) | US$41.54m |
| Revenue (TTM) | US$785.10m |
224.4x
P/E Ratio11.9x
P/S RatioIs RGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGEN income statement (TTM) | |
|---|---|
| Revenue | US$785.10m |
| Cost of Revenue | US$362.43m |
| Gross Profit | US$422.67m |
| Other Expenses | US$381.13m |
| Earnings | US$41.54m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.74 |
| Gross Margin | 53.84% |
| Net Profit Margin | 5.29% |
| Debt/Equity Ratio | 26.1% |
How did RGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/11 21:45 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Repligen Corporation is covered by 31 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Hugo Solvet | BNP Paribas |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |